ImmuPharma (IMM) Shares Fell 18.4% on the Final FY ’22 Results

The ImmuPharma PLC (LON: IMM) share price fell 18.4% after releasing its final results for the year ended 31 December 2022. The company lost £3.8 million, marking a significant improvement to the £8.2 million loss it incurred in the previous year. 

The company’s research and development spending fell to £2.0 million from £3.7 million in 2021, while its administrative expenses dropped to £0.8 million from £1.0 million in 2021. As a result, the company had zero exceptional items in 2022 compared to exceptional items worth £1.4 million from corporate reorganisation costs in 2021.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

ImmuPharma had a cash balance of £0.7 million as of 31 December 2022, compared to £1.6 million in December 2021, despite raising £2.0 million via a share subscription in August 2022. The company also had other financial assets worth over £1.0 million. 

Other operational milestones achieved by the company include P140 Pharmacokinetic (PK) study completed in April 2022, with critical findings shared with the FDA. In addition, in February 2023, an adaptive Phase 2/3 study for Lupuzor™ in SLE/Lupus patients was agreed upon with US partner Avion Pharmaceuticals, following guidance from the FDA.

ImmuPharma has also confirmed a Type C meeting with the FDA for 7 June 2023, where the FDA will consider its new protocol of the Phase 2/3 adaptive study for Lupuzor™ in SLE patients. 

There is also a Pre-IND meeting confirmed with the FDA for 16 May 2023, where the FDA will hive feedback on the new protocol for the Phase 2/3 adaptive clinical trial for CIPD.

Tim McCarthy, ImmuPharma’s CEO, commented: “As a Board, we remain focused on bringing our two key late-stage clinical assets, Lupuzor™ for lupus and CIDP, closer to the market. We now have a clinical roadmap for Lupuzor™ and remain on track to commence the Phase 2/3 adaptive trial in H2 2023, with potential CIDP moving into clinical studies in parallel. This illustrates the potential franchise we have within our P140 autoimmune platform.”

The CEO added that the firm would remain focused on commercial and partnering opportunities while closely monitoring its cost base.

*This is not investment advice. 

ImmuPharma (IMM) share price. 

The ImmuPharma share price fell 18.4% to trade at 2.35p, from Wednesday’s closing price of 2.88p.